Table 3. Sub-group analysis based on study characteristics.

Sub-group	No. of studies for PFS	HR (95%CI)	No. of studies for OS	OS (95%CI)
Phases
Phase II	4 [28] , [29], [31], [32]	0.94 (0.80–1.09)	4 [28] , [29], [31], [32]	0.82 (0.70–0.97)
Phase III	2 [27] , [30]	0.71 (0.55–0.92)	2 [27] , [30]	0.94 (0.84–1.06)
EGFR-status
Wild type	3 [28] , [29], [30]	0.65 (0.42–0.88)	5 [27] , [28], [29], [30], [31]	0.92 (0.75–1.12)
Mutation	2 [28] , [30]	1.20 (0.41–1.97)	3 [27] , [30], [31]	0.91 (0.40–1.43)
KRAS status
Wild type	1 [28]	1.01 (0.63–1.60)	1 [32]	0.71 (0.43–1.18 )
Mutation	1 [28]	0.18 (0.05–0.70)	2 [28] , [32]	0.37 (0.12–1.09)